CLENPIQ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) by Ferring Pharmaceuticals is acidifying activity [moa]. First approved in 2017.
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
CLENPIQ is an oral bowel-cleansing solution combining sodium picosulfate, magnesium oxide, and anhydrous citric acid to prepare patients for colonoscopy and other GI procedures. It works through acidifying activity to soften stool and promote evacuation, making it a non-invasive preparation aid. The product is indicated for adult patients requiring bowel cleansing prior to diagnostic or therapeutic GI procedures.
Product is at peak lifecycle with modest Part D spending (~$33M annually) and stable utilization, supporting a lean, optimized commercial team focused on market maintenance.
Acidifying Activity
Calculi Dissolution Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy
Effects and Tolerability With Clenpiq and Low Residue Diet
Comparison of Clenpiq vs Golytely Bowel Preparation
Working on CLENPIQ positions you in a stable, profitable GI franchise at Ferring Pharmaceuticals with strong commercial and medical affairs teams. The 92 linked positions and peak-lifecycle status indicate a mature organization focused on market optimization, customer relationships, and patient access—ideal for building execution excellence in specialty pharma.
Worked on CLENPIQ at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
92 open roles linked to this drug
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo